Rin Yamada
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Year:
2026
Glioblastoma (GBM) involves disruptions in the blood–brain barrier (BBB) and alterations in the immune microenvironment, including the activation of glioma‐associated macrophages (GAMs). Vascular endothelial growth factor inhibitors, commonly used in recurrent GBM treatment, can influence these processes. This study investigates the relationship between BBB disruption and GAM activation, focusing on plasmalemma vesicle‐associated protein (PLVAP), a marker of BBB disruption, and α1‐acid glycoprotein (AGP), an inflammatory protein implicated in tumor progression. PLVAP expression was analyzed by immunohistochemistry (IHC) in human GBM samples to determine correlations with tumor grade, proliferation, and GAM activation. Pre‐ and post‐bevacizumab treatment GBM samples were compared to assess changes in BBB integrity and macrophage activity. AGP's role in GAM activation was studied through in vitro assays and glioma implantation in AGP knockout mice, with assessments of tumor growth and angiogenesis. Results showed elevated PLVAP expression in higher‐grade gliomas, correlating with increased tumor proliferation and GAM activation, particularly around PLVAP‐positive vessels. Bevacizumab treatment reduced PLVAP expression and macrophage activity. AGP localized to regions of BBB disruption, promoting macrophage‐mediated tumor growth in vitro. AGP knockout mice demonstrated reduced angiogenesis and prolonged survival. Spatial analysis revealed increased expression of macrophage‐inducing molecules near PLVAP‐positive vessels. These findings suggest PLVAP as a marker of BBB disruption and glioma malignancy. AGP, associated with BBB leakage, contributes to GAM activation and tumor progression, highlighting its potential as a therapeutic target for GBM.
Year:
2025
Oral squamous cell carcinoma (OSCC) is one of the most common head and neck cancers, and immunotherapy targeting programmed cell death 1 (PD‐1) has become a treatment option for recurrent OSCC after surgery and radiation therapy. However, few studies have identified definitive biomarkers for predicting patient response to anti‐PD1 therapy in OSCC. In the present study, biopsy specimens were obtained from 23 patients with recurrent OSCC who were subsequently treated with anti‐PD1 therapy. Immunohistochemical examinations of CD3, CD8, FOXP3, CD103, CD163, programmed cell death ligand 1 (PD‐L1), HLA‐A/B/C, HLA‐DR, and β2 microglobulin were performed, and their correlation with clinical response was statistically analyzed. We found that an increased density of CD8‐positive lymphocytes and increased PD‐L1 expression predicted a favorable response to anti‐PD1 therapy in recurrent OSCC. In contrast, clinical factors such as age and sex, and immune‐related factors such as HLA‐Classes I and II, were not associated with the response to anti‐PD1 therapy. Taken together, our results suggest that immunohistochemical analysis of CD8 and PD‐L1 may be useful for predicting the efficacy of anti‐PD1 therapy in recurrent OSCC.
Year:
2025
Recent advances in anti-cancer therapy have indicated the significance of the tumour immune microenvironment in tumour progression and resistance to anti-cancer therapy. This study investigated primary colorectal cancer (CRC) tissues resected from 180 cases in a single institute in a region highly endemic for human T-cell leukaemia virus type 1 (HTLV-1) carriers. Among those 180 cases, 35 HTLV-1 carriers were identified. CRC patients who were HTLV-1 carriers were significantly older (mean age: 76.9 vs. 72.7 years, P = 0.0341), with a lower incidence of lymph node metastases (pN0: 91% vs. 65%, P = 0.0085), and lower tumour stages (stage III or IV: 11% vs. 36%, P = 0.0117) compared to non-carriers. HTLV-1 carriers tended to show a lower incidence of relapse, although the difference was not significant ( P = 0.2272). The density of forkhead box P3-positive regulatory T cells (Tregs) was significantly higher in HTLV-1 carriers (median density: 132 vs. 89 cells/mm 2 , P = 0.0051). In situ hybridisation showed cells positive for HTLV-1 basic leucine zipper factor , likely representing lymphocytes located in stroma around the cancer nest. Our findings indicate that lymph node metastasis was significantly suppressed in CRC patients infected with HTLV-1. Since HTLV-1 infection reportedly impairs the immunosuppressive functions of Tregs, anti-cancer immune responses are potentially enhanced in CRC patients who are HTLV-1 carriers.
Year:
2025
Background CD169 + macrophages in lymph nodes (LNs) activate cytotoxic T lymphocytes (CTLs), which play a crucial role in anticancer immunity, through antigen presentation and co-stimulation by CD169. Interferon alpha (IFNα) is capable of inducing the CD169 + phenotype of macrophages; however, its clinical applications have been hindered by pharmacokinetic limitations—low LN distribution and an inability to target macrophages. To overcome these issues, this study genetically fused mouse IFNα (mIFNα) with mannosylated mouse serum albumin (Man-MSA), and investigated the antitumor effects of the hybrid protein (Man-MSA-mIFNα) or its add-on effects with programmed death-ligand 1 (PD-L1) blockade. Methods To confirm the possibility of CD169 + macrophage-mediated T cell priming, positional information about individual immune cells in LNs of cancer patients was obtained. Traits of Man-MSA-mIFNα, which was prepared using Pichia pastoris to form the high-mannose structure, were characterized by several physicochemical methods. To evaluate the lymphatic drainage of Man-MSA-mIFNα, radioiodine or Cy5-labeled Man-MSA-mIFNα was subcutaneously administered in mice, and then the radioactivity or fluorescence in LNs was analyzed. CD169-diphtheria toxin (DT) receptor (CD169-DTR) mice in which LN CD169 + macrophages can be depleted by DT injection were used to verify whether the antitumor effect of Man-MSA-mIFNα is dependent on LN CD169 + macrophages. Results Multiplex tissue imaging predicted close proximity of CD169 + macrophages and T cells and positive correlation between the number of CD169 + macrophages and T cells in neighborhoods in LNs of cancer patients. Physicochemical analyses showed that Man-MSA-mIFNα was formed from the fusion of the intact Man-MSA and mIFNα. Man-MSA-mIFNα efficiently induced the CD169 + phenotype of macrophages by its high LN distribution and macrophage-targeting capability, and significantly exerted antitumor activity through CD8 + T cell activation in the LNs, whereas its antitumor effects were canceled in CD169-DTR mice. Finally, combination therapy with PD-L1 blockade markedly suppressed tumor growth in MB49-bearing mice, which exhibit resistance to PD-L1 blockade monotherapy. Conclusions The present study successfully designed and developed Man-MSA-mIFNα, which efficiently induces the CD169 + phenotype in LN macrophages, contributing to the antitumor immunity. The findings suggest that our novel strategy targeting CD169⁺ macrophages could be a promising immunotherapy for cancer patients who are unresponsive to immune checkpoint inhibitors. Graphical Abstract
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Introduction: Extrahepatic cholangiocarcinoma (eCCA) is an aggressive malignancy with a poor prognosis. Immune checkpoint inhibitors (ICIs) targeting PD-L1 enhance antitumor immunity, but reliable predictive biomarkers remain unclear. This study investigated tumor-infiltrating immune cells, including T cells and macrophages, as potential biomarkers for ICI efficacy in eCCA. Methods: A retrospective analysis was conducted on 15 eCCA patients who received durvalumab for recurrent or unresectable disease after surgery. Immunohistochemical staining assessed PD-L1, HLA-class I/II, CD8, and CD103 expression in resected tumor specimens. ICI response was evaluated using RECIST 1.1 criteria and classified as partial response (PR), stable disease (SD), or progressive disease (PD). Correlations between immune cell infiltration and clinical outcomes were analyzed. Results: Five patients achieved PR, five SD, and five PD. CD8+ and CD103+ T-cell infiltration within tumor nests was significantly higher in PR and SD groups than in PD (p = 0.032, p = 0.0147). High HLA-class I expression correlated with response, while PD-L1 and HLA-class II showed no significant association. Patients with increased CD8+CD103+ T cells demonstrated better disease control. Conclusion: Intratumoral CD8+ and CD103+ T cells may serve as predictive biomarkers for ICI efficacy in eCCA, highlighting tissue-resident immune cells as therapeutic targets.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (5)
Lianbo Li
Kumamoto University
Yuji Miyamoto
Kumamoto University
Toshihide Tanaka
Jikei University School of Medicine
Hiromu Yano
Assistant Professor (Tenure-track)
Kumamoto University
Toru Takeo
Professor
Kumamoto University
Make your next move.
Prepare your application
Review drafts before you send them.